NeoGenomics Laboratories  

12701 Commonwealth Drive
Suite 9
Fort Myers,  FL  33913

United States
http://www.neogenomics.org
  • Booth: 26117

NeoGenomics specializes in cancer genetics testing and information services with the most comprehensive oncology-focused testing menus globally to diagnose and treat cancer. NeoGenomics operates CLIA certified laboratories serving the needs of pathologists, oncologists, academic centers, hospital systems, Pharma, and managed care organizations. Visit http://neogenomics.com/ to learn more about our global locations.


 Products

  • NeoVUE™ Point-and-Click Visualization Booth 26117
    NeoVUE™ contains intuitive point-and-click visualization of IF images, classification label maps, tumor segmentation masks, and color blends, and creates user-defined channel groups for specific phenotypes based on marker co-expression....

  • NeoVUETM Image and Data Visualization Software for MultiOmyxTM

    The presence of unique subclasses of immune cells in the tumor microenvironment (TME) have been shown to influence the tumor response to therapy in different types of cancers. For a comprehensive analysis uncovering the relationships between tumor cells, stromal cells, and immune cells NeoGenomics offers MultiOmyx™, a proprietary, multiplexing methodology that enables analysis of dozens of proteins in a single FFPE tissue section. This protein immunofluorescence (IF) assays utilize a pair of directly conjugated Cyanine dye-labeled (Cy3, Cy5) antibodies per round of staining. Each round of staining is imaged and followed by novel dye inactivation chemistry, enabling repeated rounds of staining and deactivation. Proprietary cell segmentation algorithms generate unique IDs for every cell allowing them to be tracked through multiple rounds of staining and deep learning based cell classification algorithms then identify positive cells for each biomarker.

    As a novel MultiOmyx™ feature, NeoGenomics will now be providing the image and data visualization software NeoVUE™ to complement the data output and images generated with this technology. This software contains intuitive point-and-click visualization of IF images, classification label maps, tumor segmentation masks, and color blends, and creates user-defined channel groups for specific phenotypes based on marker co-expression. Images can be viewed in a web browser remotely on Windows, macOS or Linux and it supports panning, zooming, and rotation of large images. In addition to the visualization tool, the NeoVUE™ software also enables the user to interrogate study data via scatter plots, heat maps and filters for quantitative cell counts for individual or combinations of markers. The user interface also allows users to transition seamlessly between quantitative data and study images. Areas of an image can be annotated with a variety of figures and measurements, and custom tags can be assigned to slides to differentiate Pre from Post treatment samples. It supports collaborations by allowing authorized users to join individual or group sessions in real-time, and last but not least publication efforts are supported by the ability to export both IF grayscale images and color-blend images as TIFFs or other supported formats.

    MultiOmyx™ multiplexing methodology provides a deeper understanding of the complexity of the functions of distinct tumor-infiltrating lymphocytes (TILs), myeloid cells, and immune cells within the TME. With the NeoVUE™ image and data visualization software the MultiOmyx™ end-user will now be allowed to view, manage, and rapidly analyze the multiplexed images as well as the comprehensive biomarker profiling on a single-cell level.  

  • PIK3CA CDx Testing Program - Booth 26117
    PIK3CA CDx Mutation Analysis Informing Sequencing Decisions in Advanced Breast Cancer PIK3CA Companion Diagnostic Testing Program Available exclusively through NeoGenomics designed to ensure access to testing for patients eligible for PIQRAY....

  • The PIK3CA gene encodes the p110 alpha catalytic subunit of PI3K enzymes. Mutations occur in a wide variety of tumors and may have prognostic and therapeutic significance, depending on tumor type. Numerous PI3K-pathway inhibitors are in development.

    *PIQRAY (alpelisib) is an alpha-specific PI3K inhibitor indicated for patients with HR+/HER2- PIK3CA mutated, advanced or metastatic breast cancer that have progressed on endocrine therapy2 PIQRAY is a licensed product of Novartis Pharmaceuticals.

    • The Companion Diagnostic Testing Program is designed tensure access to testing for patients eligible for PIQRAY
    • To use this program, the laboratory or clinician must fill out the appropriate PIK3CA Companion Diagnostic Testing Program Order Form
    • Eligible patients may receive one PIK3CA CDx test resultunder testing program

    Get started! Learn more in booth 26117. Talk to a representative for PIK3CA Companion Diagnostic Testing Order Forms.